Image Place holder

Ricardo Costa, MD, MSc


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Costa is an Assistant Member in the Department of Breast Oncology at Moffitt Cancer Center. Dr. Costa received his MD degree at the School of Medicine, Federal University of Pernambuco, Recife, Brazil. He completed an Internal Medicine Residency at East Tennessee State University, Johnson City, Tennessee. He also completed a Hematology/Oncology Fellowship in the Division of Hematology/Oncology, Department of Medicine, Drexel of Pittsburgh, Allegheny General Hospital, Pittsburgh, Pennsylvania. In parallel Dr.Costa acquired a master degree in clinical research at University of Pittsburgh. Following his Fellowship, Dr. Costa was a Medical Oncologist at Real Hospital Portugues, Recife, PE, Brazil. Dr. Costa has recently been an Instructor at the Developmental Therapeutics Program at Northwestern University Feinberg School of Medicine, in the Division of Hematology/Oncology, Department of Medicine, Chicago, Illinois. Dr. Costa is interested in the multidisciplinary care of patients with breast cancer in all stages. His research interest is in breast cancer clinical studies with a special focus on new drug development in the realm of immunotherapy and targeted therapies for the treatment of breast cancer.

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • Drexel of Pittsburgh Allegheny General Hospital - Hematology/Oncology
  • Northwestern University Feinberg School of Medicine - Developmental Therapeutics

Residency:

  • East Tenessee State University - Internal Medicine

Medical School:

  • Federal University of Pernambuco, Brazil - MD
Participating Trials

CLINICAL TRIAL 17835
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Condition: Breast
Intervention: Not Applicable; Paraplatin (carboplatin); Placebo; Taxol (paclitaxel); Veliparib (ABT-888); carboplatin; paclitaxel
Open

CLINICAL TRIAL 18649
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination with Folate Receptor Alpha Peptides with GM-CSF in Patients with Triple Negative Breast Cancer Defined as Primary Tumor that is Her2-neu Negative and Low (< 10%) ER/PR Nuclear Staining.
Condition: Breast
Intervention: FR alpha peptide vaccine; GM-CSF; Leukine (GM-CSF); cyclophosphamide; cytoxan (cyclophosphamide); sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition: Breast
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 18862
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); SGN-LIV1A; Trastuzumab; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention: AMG 386; Adriamycin (doxorubicin); BMN-673 (Talazoparib); CPT-11 (irinotecan); Camptosar (irinotecan); Ganetespib (STA-9090); Ganitumab; Herceptin (Trastuzumab); MK-2206; Not Applicable; PLX3397; Patritumab; Pembrolizumab (Keytruda); Pertuzumab; T-DM1; Talazoparib; Taxol (paclitaxel); Trastuzumab; U3-1287 (Patritumab); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; irinotecan; paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18205
A Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Condition: Breast
Intervention: Ferumoxytol; MM-398
Open

CLINICAL TRIAL 18079
Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Condition: Breast
Intervention: E75; GM-CSF; Herceptin (Trastuzumab); Leukine (GM-CSF); Placebo; sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 18977
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Condition: Breast
Intervention: G1T28 (Trilaciclib); Gemzar (gemcitabine); Paraplatin (carboplatin); Trilaciclib; carboplatin; gemcitabine
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol. 2017 Sep;117:114-127. Pubmedid: 28600175.
  • Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017 May;10(1):101. Pubmedid: 28476164. Pmcid: PMC5420131.
  • Costa RLB, Gradishar WJ. Triple-Negative Breast Cancer: Current Practice and Future Directions. J Oncol Pract. 2017 May;13(5):301-303. Pubmedid: 28489982.
  • Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017 Jun;9:207-213. Pubmedid: 28652812. Pmcid: PMC5476791.
  • Mota JM, Collier KA, Costa RLB, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. Oncotarget. 2017 Jun. Pubmedid: 28645115.
  • Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Jun. Pubmedid: 28733528.
  • Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2017 Jul. Pubmedid: 28674764.
  • Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan;8(5):8910-8920. Pubmedid: 27852042. Pmcid: PMC5352453.
  • Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget. 2017 Feb;8(7):12417-12432. Pubmedid: 27926493. Pmcid: PMC5355355.
  • Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb;8(9):16052-16074. Pubmedid: 28030802. Pmcid: PMC5362545.
  • Agulnik M, Costa RL, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2016 Oct. Pubmedid: 27771610.
  • Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2016 Oct. Pubmedid: 27701069.
  • Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016 Oct;7(40):65364-65373. Pubmedid: 27588476. Pmcid: PMC5323161.
  • Costa R, Carneiro BA, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ. The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget. 2016 Jul;7(29):46734-46749. Pubmedid: 27102148. Pmcid: PMC5216833.
  • Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016 Feb;10:873-884. Pubmedid: 27013865. Pmcid: PMC4778792.
  • Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016 Aug;7(34):55924-55938. Pubmedid: 27409839. Pmcid: PMC5342462.
  • Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ. Is Personalized Medicine Here?. Oncology (Williston Park). 2016 Apr;30(4):293-303, 307. Pubmedid: 27085327.
  • Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014 Jun;2014:952624. Pubmedid: 24900933. Pmcid: PMC4037124.
  • Costa R, Costa R, Bacchi CE, Almeida Filho P. Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol. 2014 Jan;2013:252159. Pubmedid: 24455330. Pmcid: PMC3877610.
  • Costa R, Costa R, Costa R. Follicular lymphoma presenting with leptomeningeal disease. Case Rep Hematol. 2014 Dec;2014:767621. Pubmedid: 25544910. Pmcid: PMC4269308.
  • Costa R, Costa RB, Bacchi C, Sarinho F. Adenocarcinoma of the lung presenting with atypical cystic brain lesions. BMJ Case Rep. 2014 Apr;2014. Pubmedid: 24717598. Pmcid: PMC3987522.
  • Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013 Mar;32 Suppl 1:S79-S82. Pubmedid: 20556455.
  • Silva Junior GB, Libório AB, Vieira AP, Bem AX, Lopes Filho AS, Figueiredo Filho AC, Guedes AL, Souza JH, Costa CM, Costa R, Daher EF. Evaluation of renal function in sickle cell disease patients in Brazil. Braz J Med Biol Res. 2012 Jul;45(7):652-655. Pubmedid: 22584642. Pmcid: PMC3854265.
  • Barros Costa RL. Targeted therapy: comprehensive review. Am J Hosp Palliat Care. 2009 Apr;26(2):137-146. Pubmedid: 19229068.
  • Costa R, Costa-Filho RB, Talamantes SM, Queiroga F, Campello EC, Cartaxo H, Costa RB. Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review. Case Rep Oncol. 10(2):524-530. Pubmedid: 28690527. Pmcid: PMC5498939.